CL2008003919A1 - Compuestos derivados de y-lactona del acido 15a,16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxilico; composicion farmaceutica que lo contiene y su uso para preparar medicamento para la contracepcion oral y para trastornos pre, peri y postmenopausicos. - Google Patents

Compuestos derivados de y-lactona del acido 15a,16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxilico; composicion farmaceutica que lo contiene y su uso para preparar medicamento para la contracepcion oral y para trastornos pre, peri y postmenopausicos.

Info

Publication number
CL2008003919A1
CL2008003919A1 CL2008003919A CL2008003919A CL2008003919A1 CL 2008003919 A1 CL2008003919 A1 CL 2008003919A1 CL 2008003919 A CL2008003919 A CL 2008003919A CL 2008003919 A CL2008003919 A CL 2008003919A CL 2008003919 A1 CL2008003919 A1 CL 2008003919A1
Authority
CL
Chile
Prior art keywords
pregna
peri
methylene
hydroxy
carboxylic acid
Prior art date
Application number
CL2008003919A
Other languages
English (en)
Inventor
Klar U
Kuhnke J
Bohlmann R
Huebner J
Ring S
frenzel T
menges F
Borden S
Muhn H
Prelle K
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40548690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2008003919A1 publication Critical patent/CL2008003919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuesto derivado de gama-lactona del ácido 15,16-metilen-17-hidroxi-19-nor-17-pregna-4,20(z)-dien-3-ona-21-carboxílico, dispositivo intrauterino que lo contiene y su uso para la contracepción oral y para trastornos pre, peri y postmenopáusicos.
CL2008003919A 2007-12-29 2008-12-29 Compuestos derivados de y-lactona del acido 15a,16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxilico; composicion farmaceutica que lo contiene y su uso para preparar medicamento para la contracepcion oral y para trastornos pre, peri y postmenopausicos. CL2008003919A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063495A DE102007063495A1 (de) 2007-12-29 2007-12-29 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
CL2008003919A1 true CL2008003919A1 (es) 2010-05-07

Family

ID=40548690

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003919A CL2008003919A1 (es) 2007-12-29 2008-12-29 Compuestos derivados de y-lactona del acido 15a,16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxilico; composicion farmaceutica que lo contiene y su uso para preparar medicamento para la contracepcion oral y para trastornos pre, peri y postmenopausicos.

Country Status (26)

Country Link
US (2) US20100311702A1 (es)
EP (1) EP2238149B1 (es)
JP (1) JP5600071B2 (es)
KR (1) KR20100102136A (es)
CN (1) CN101910192B (es)
AR (1) AR069962A1 (es)
AU (1) AU2008342916A1 (es)
BR (1) BRPI0821666A2 (es)
CA (1) CA2710495C (es)
CL (1) CL2008003919A1 (es)
CO (1) CO6290675A2 (es)
DE (1) DE102007063495A1 (es)
DO (1) DOP2010000199A (es)
EA (1) EA201000982A1 (es)
EC (1) ECSP10010315A (es)
ES (1) ES2539121T3 (es)
HK (1) HK1151532A1 (es)
IL (1) IL206019A0 (es)
NZ (1) NZ586453A (es)
PA (1) PA8810701A1 (es)
PE (1) PE20091336A1 (es)
TW (1) TW200940074A (es)
UA (1) UA98834C2 (es)
UY (1) UY31580A1 (es)
WO (1) WO2009083272A2 (es)
ZA (1) ZA201005395B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES

Also Published As

Publication number Publication date
EA201000982A1 (ru) 2011-02-28
US20130123219A1 (en) 2013-05-16
DOP2010000199A (es) 2010-10-15
BRPI0821666A2 (pt) 2015-06-16
WO2009083272A3 (de) 2009-08-27
JP5600071B2 (ja) 2014-10-01
UA98834C2 (ru) 2012-06-25
US20100311702A1 (en) 2010-12-09
AR069962A1 (es) 2010-03-03
CA2710495C (en) 2015-04-28
AU2008342916A1 (en) 2009-07-09
EP2238149A2 (de) 2010-10-13
PE20091336A1 (es) 2009-10-04
CO6290675A2 (es) 2011-06-20
CA2710495A1 (en) 2009-07-09
CN101910192A (zh) 2010-12-08
EP2238149B1 (de) 2015-03-18
NZ586453A (en) 2012-05-25
ES2539121T3 (es) 2015-06-26
JP2011507928A (ja) 2011-03-10
KR20100102136A (ko) 2010-09-20
CN101910192B (zh) 2013-07-31
DE102007063495A1 (de) 2009-09-17
PA8810701A1 (es) 2009-12-16
TW200940074A (en) 2009-10-01
HK1151532A1 (es) 2012-02-03
WO2009083272A2 (de) 2009-07-09
IL206019A0 (en) 2010-11-30
US8987239B2 (en) 2015-03-24
ZA201005395B (en) 2012-01-25
UY31580A1 (es) 2009-08-03
ECSP10010315A (es) 2010-08-31

Similar Documents

Publication Publication Date Title
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
ECSP066715A (es)
ECSP055685A (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
DOP2011000218A (es) Derivados de sulfonamida
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
RS51563B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
BRPI0607413A2 (pt) composição farmacêutica compreendendo derivados de indolilmaleimida
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
CL2011002100A1 (es) Composicion farmaceutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administracion por mucosa oral, nasal o a traves de la piel; y su uso para el tratamiento de la enfermedad de parkinson.
CL2008003919A1 (es) Compuestos derivados de y-lactona del acido 15a,16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxilico; composicion farmaceutica que lo contiene y su uso para preparar medicamento para la contracepcion oral y para trastornos pre, peri y postmenopausicos.
GT200600272A (es) Moduladores no esteroides de receptores de progesterona
BRPI0721255B8 (pt) composições de olopatadina para administração nasal tópica
CL2004000779A1 (es) Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en